Key Drivers
- Very high margins
- Strong FCF generation
- Negative equity
AIAI Summary
BCRX has shifted from binary biotech risk to a cash‑flowing specialty pharma where ORLADEYO's high‑margin FCF materially de‑risks near‑term funding and enables value creation via deleveraging or targeted HAE bolt‑ons, but the stock's re‑rating hinges on disciplined capital allocation given sizable debt and negative equity. Monitor multi‑quarter ORLADEYO revenue/margin sustainability, concrete debt reduction or conservative refinancing of the Astria facility, and early Astria integration/market‑share proof points to validate upside (or conversely, watch for share loss or integration missteps that would justify the low multiples).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high margins
- •Strong FCF generation
- •Negative equity
BCRX delivers very high margins and strong free cash flow with low valuation multiples, but carries heavy long-term leverage and negative equity that create material solvency risk despite adequate short-term liquidity.
Price Behavior
Key Price Behavior Insights:
- •Strong uptrend
- •Catalyst gap
- •Elevated volatility
BCRX has shown a strong short-term uptrend over the last month (≈+30% to $9.70) with momentum-fueled acceleration around mid‑March that raises breakout upside if it clears $9.81 but also increases short-term pullback risk.
Sharp gap to $9.30 mid‑March from the prior $8.20–$8.80 band indicating catalyst-driven volatility
Sentiment & News
Key News Insights:
- •Strong revenue
- •Analyst upgrades
- •Institutional trimming
BioCryst beat Q4 estimates and reported 38% ORLADEYO revenue growth for 2025, earning a “Moderate Buy” consensus despite some institutional trimming and recent RSU grants.
The results and consensus should support near-term share momentum, though investor sell-downs and incremental equity grants could cap upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings